Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | June 12, 2026 | June 15, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | EVP, CFO and Treasurer | February 14, 2025 | February 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,536 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 40,011 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 38,536 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F4: This award is fully vested in accordance with its terms. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy the Brian P. McKeon Trust | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,000 F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares are held by The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), of which the reporting person and his wife are the trustees and members of the reporting person's immediate family are the beneficiaries.
F3: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F4: This award is fully vested in accordance with its terms.
DENTSPLY SIRONA Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy a Trust | 10,000 |
Reported balance
After 2026-06-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 10,000 · Balance 10,000 |
| Common StockSEC Table I · non-derivative | Direct | 28,887 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28,887 |
IDEXX LABORATORIES INC /DE
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,208.5926 |
Reported balance
After 2025-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-14 · Exercise / conversion · Acquired 252 · Balance 31,208.5926 F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 31,511.5926 |
Reported balance
After 2025-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-02-14 · Exercise / conversion · Acquired 303 · Balance 31,511.5926 |
| Common StockSEC Table I · non-derivative | Direct | 31,819.5926 |
Reported balance
After 2025-02-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-02-14 · Exercise / conversion · Acquired 308 · Balance 31,819.5926 |
| Common StockSEC Table I · non-derivative | Direct | 32,118.5926 |
Reported balance
After 2025-02-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-02-14 · Exercise / conversion · Acquired 299 · Balance 32,118.5926 |
| Common StockSEC Table I · non-derivative | Direct | 31,549.5926 |
Reported balance
After 2025-02-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-02-14 · Tax withholding · Disposed 569 · Balance 31,549.5926 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-14 · Exercise / conversion · Disposed 252 · Balance 0 F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 303 |
Reported balance
After 2025-02-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-14 · Exercise / conversion · Disposed 303 · Balance 303 F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 615 |
Reported balance
After 2025-02-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-14 · Exercise / conversion · Disposed 308 · Balance 615 F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 894 |
Reported balance
After 2025-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-14 · Exercise / conversion · Disposed 299 · Balance 894 F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025. |
| Common StockSEC Table I · non-derivative | Indirectby Estony McKeon Family, LLC | 18,050 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 18,050 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022.
F3: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2023.
F4: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2024.
F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ATHENAHEALTH INC
Report date February 11, 2019 · Filed February 13, 2019
Section 16 reporting ended · disclosed 2019-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-11 transaction · row 1
1 source rowRow 1 · 2019-02-11 · Disposition to issuer · Disposed 2,721 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes. F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of November 11, 2018, among athenahealth, Inc. (the "Company"), May Holding Corp., and May Merger Sub Inc. (the "Merger Agreement"), on February 11, 2019, each share of athenahealth common stock, par value $0.01 ("Common Stock") issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) and not otherwise excluded pursuant to the terms of the Merger Agreement, was converted into the right to receive $135.00 per share in cash (the "Merger Consideration"), subject to any required withholding taxes.
F2: 1,931 of these securities represent shares of Common Stock underlying athenahealth restricted stock unit ("RSU") awards subject to time-based vesting. Pursuant to the Merger Agreement, on February 11, 2019, unvested RSUs outstanding immediately prior to the Effective Time were canceled and converted into the right to receive the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,128 | $571.84 | $4,076,061.98 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,398.5926 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $571.36 to a high of $572.33 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,675 | $570.97 | $3,240,253.05 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,526.5926 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $570.345 to a high of $571.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,912 | $569.91 | $2,229,500.44 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,201.5926 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $569.34 to a high of $570.34 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,469 | $568.84 | $835,633.16 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,113.5926 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $568.33 to a high of $569.28 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,564 | $567.35 | $887,333.37 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,582.5926 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $566.92 to a high of $567.86 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 701 | $566.53 | $397,139.63 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,146.5926 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $565.89 to a high of $566.84 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,581 | $564.98 | $893,227.06 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,847.5926 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $564.63 to a high of $565.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 615 | $563.82 | $346,746.72 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,428.5926 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $563.48 to a high of $564.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 23,326 | $141.60 | $3,302,961.60 |
DisclosureSEC source: 0000874716-24-000015 · wk-form4_1707516080.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,043.5926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 25.247 shares purchased under the Issuer Employee Stock Purchase Plan on September 29, 2023 and December 29, 2023. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,802.88 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,128.66 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 313 | $24.24 Strike: $24.24 | $7,587.12 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 7 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,990 Underlying: Ordinary Shares · 313 shares Expires 2031-06-14 F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 88 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,533 Underlying: Ordinary Shares · 88 shares Expires not disclosed F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: This award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 523 | $22.48 Strike: $22.48 | $11,757.04 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,692 Underlying: Ordinary Shares · 523 shares Expires 2031-02-10 F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 22:11 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 90 | $22.48 Strike: $22.48 | $2,023.20 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,639 Underlying: Ordinary Shares · 90 shares Expires 2031-02-10 F3 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000107 · wk-form4_1691531977.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,704 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 117 | $504.08 | $58,977.36 |
DisclosureSEC source: 0000874716-23-000107 · wk-form4_1691531977.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,692.3456 F2 · price: Closing price of Issuer common stock on NASDAQ market on August 4, 2023. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:59 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 192 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-23-000107 · wk-form4_1691531977.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,809.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020549 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:34 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,430 | $29.88 | $42,728.40 |
DisclosureSEC source: 0001127602-23-020549 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,696 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020549 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:35 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019631 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:35 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019631 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| May 05, 2023 Filed May 8, 2023 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 560 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0000874716-23-000042 · wf-form4_168357975138231.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant. Read SEC document |
| May 05, 2023 Filed May 8, 2023 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 560 | $178.26 | $99,825.60 |
DisclosureSEC source: 0000874716-23-000042 · wf-form4_168357975138231.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,605.3456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 14.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · derivative · entry 12 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,896 Underlying: Common Stock · 303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,199 Underlying: Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · derivative · entry 10 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,452 Underlying: Common Stock · 433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F6 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · derivative · entry 9 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,885 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F6 · price: Not applicable. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · derivative · entry 8 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 Underlying: Common Stock · 504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F6 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,208 | $503.65 | $608,409.20 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 6 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,030.6426 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 303 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,238.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,935.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,682.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,249.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:53 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 504 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003220 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,814.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 01:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 4,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-004585 · form4.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,445 Underlying: Ordinary Shares · 4,445 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 2/10/2022. Read SEC document |
| February 10, 2023 Filed Feb 11, 2023 01:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 4,445 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-004585 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 5 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,824 Underlying: Common Stock · 1,231 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F5 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F4 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 201 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2033-02-07 F5 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 8,811 | Not disclosed Strike: $497.43 | Not disclosed |
DisclosureSEC source: 0001567619-23-002394 · doc1.xml · derivative · entry 3 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,811 Underlying: Common Stock · 8,811 shares Expires 2033-02-07 F5 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 192 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015174 · doc1.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 192 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 90 | $407.78 | $36,700.20 |
DisclosureSEC source: 0001567619-22-015174 · doc1.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,275.6426 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 192 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-015174 · doc1.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Executive VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,365.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 20 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022 and June 30, 2022. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,554 | $0.00 Strike: $31.48 | $0.00 |
DisclosureSEC source: 0001127602-22-019129 · form4.xml · derivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019129 · form4.xml · derivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017638 · form4.xml · derivative · entry 4 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 795 | $27.19 | $21,616.05 |
DisclosureSEC source: 0001127602-22-017638 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,724 Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:57 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017638 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.